Loading...
•
Jun 30, 2020
Capricor Q2 2020 Earnings Report
Capricor reported financial results for the second quarter ending June 30, 2020 and provided a corporate update.
Key Takeaways
Capricor Therapeutics reported a net loss of $3.5 million, or $0.23 per share, for the second quarter of 2020. As of June 30, 2020, the Company’s cash, cash equivalents and marketable securities totaled approximately $36.3 million.
Capricor is underway in animal studies and have seen promising results showing the mRNA vaccine is capable of generating an antibody response to multiple antigens expressed by COVID-19.
A new investigational new drug application (IND) has been submitted to the FDA for a Phase II clinical trial to treat up to 60 patients in severe or critical condition with COVID-19 with CAP-1002.
Capricor continues to discuss next steps in its DMD program with the FDA
The company is focused on the development of the next generation of potential vaccines using its proprietary exosome platform.
Forward Guidance
Capricor is focused on advancing its exosome platform, COVID-19 and DMD programs and its anticipated milestones in 2020.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...